OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design

#2100

Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.

Aim(s): To describe the evolution of patients’ perception of information and QoL within 6 months of treatment initiation in routine clinical care.

Materials and methods: In this non-interventional, prospective, multicentre cohort study, 50 specialist physicians at French reference centres for NET care will consecutively enrol 115 patients with histologically confirmed G1 or G2 gastroentero- (GEP-)NETs for whom the decision to initiate treatmentment with lanreotide autogel 120mg /28 days has already been taken. Patients will complete self-administered questionnaires before treatment initiation, and at 3 (M3) and 6 (M6) months. Perception of information (QLQ-INFO25), QoL (QLQ-C30) and clinical parameters will be assessed at these 3 time points; coping (Brief COPE) will be assessed at baseline.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Gueguen D, Hammel P,

Keywords: patients perception of information, QoL, lanreotide,